Clinical Trials Browser

Phase 1 × Withdrawn × infigratinib × Clear all

NCT05510427 2023-08-15

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Phase 1 Withdrawn

Gastrointestinal

Liver Neoplasms, Cholangiocarcinoma

NCT04972253 2022-08-10

(BLASST)-3

Phase 1 Withdrawn

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT02312804 2015-02-16

Ph Ib/BGJ398/Cervix and Other Solid Tumors

Phase 1 Withdrawn

Uterine Cervical Neoplasms, Neoplasms